Alterations in liver function are frequently encountered in patients with type 2 diabetes ([@B1],[@B2]). Nonalcoholic fatty liver (steatosis) and hepatic insulin resistance are typical for type 2 diabetes and may even precede or contribute to its development ([@B2],[@B3]). It also relates to the development of cardiovascular diseases ([@B4]), besides the progression into steatohepatitis and cirrhosis ([@B5]). Steatosis likely results from excessive lipid overflow originating from augmented lipid stores in peripheral or visceral adipocytes, lipogenesis, or high dietary intake ([@B2]).

Magnetic resonance spectroscopy (MRS) allows noninvasive direct measurements of metabolite concentrations and tracing of metabolic fluxes in situ. Quantification of intramyocellular lipids and hepatocellular lipids (HCL) by ^1^H MRS revealed that both are linked to whole-body (peripheral) insulin resistance, abnormal endogenous glucose production (EGP), and liver glycogen storage in line with hepatic insulin resistance ([@B2]). According to one current paradigm, excessive ectopic lipid deposition precedes the development of type 2 diabetes ([@B2]). Yet, the underlying metabolic processes leading to lipid accumulation and insulin resistance in skeletal muscle and liver are not fully understood.

In skeletal muscle, insulin resistance relates not only to elevated lipids but also to impaired rates of phosphorylation (flux through ATP synthesis, fATP), as measured by ^31^P MRS in elderly ([@B6]) type 2 diabetic patients ([@B7]), their insulin-resistant first-degree relatives ([@B8]), and nondiabetic individuals with elevated plasma free fatty acids (FFAs) ([@B9]).

Although it has been suggested that nonalcoholic steatohepatitis is associated not only with insulin resistance but also with mitochondrial abnormalities ([@B10]), no data on the quantification of fATP in patients with type 2 diabetes have been reported so far in the human liver. Our previous studies showed that type 2 diabetic individuals have lower hepatic concentrations of P~I~ and ATP ([@B11]). After developing a saturation transfer experiment for assessment of hepatocellular fATP ([@B12]), we tested the hypothesis that type 2 diabetic patients have lower hepatocellular fATP than nondiabetic controls, which should relate independently of HCL to hepatic insulin resistance.

![Liver MR data of one patient with type 2 diabetes. A: Axial slice through the liver (gradient echo, prone position). The grid corresponds to the chemical shift imaging matrix. The voxels surrounded by the bold white line were selected for quantification. The MR spectrum corresponding to the "×" in the image is shown on the right panel. B: MR spectra from the saturation transfer experiment (solid line). The ATP resonance is completely suppressed, and the P~I~ signal is lower than in the baseline control experiment (dashed line).](448fig1){#F1}

RESEARCH DESIGN AND METHODS {#s5}
===========================

The study protocol conformed with the Declaration of Helsinki (2008) and was approved by the appropriate institutional ethical board. Informed consent was obtained from each study participant after explanation of the purpose, nature, and potential complications of the study.

Volunteers {#s6}
----------

After recruitment by means of public advertisement, all participants underwent complete medical history, clinical examination, and laboratory tests to exclude cardiovascular, renal, and thyroid diseases, and viral hepatitis. All volunteers were white and had already participated in our previous study on absolute quantification of liver phosphorus metabolites ([@B11]). The study excluded patients taking insulin or thiazolidinediones, or presenting with islet cell antibodies and diabetes-related complications. Controls had similar body mass and age, but normal glucose tolerance during a 75-g oral glucose tolerance test and had neither a family history of diabetes nor regular drug treatment. None of the participants was physically trained or performed regular intense exercise. They had no evidence for liver diseases and consumed \<20 g alcohol daily.

Of 24 individuals recruited, 3 did not complete the experiment because they refused to continue the MRS session. Data sets of three participants could not be used due to low quality resulting from a poor local homogeneity of the static magnetic field. Data from one individual could not be used because of a technical problem with the scanner. Thus, complete MRS datasets for 17 individuals were available for analyses ([Table 1](#T1){ref-type="table"}).

###### 

Anthropometric and laboratory parameters

  Variable                          Type 2 diabetes                               Control
  --------------------------------- --------------------------------------------- -------------
  *N* (female)                      9 (3)                                         8 (4)
  Age (years)                       57.7 ± 6.1                                    60.1 ± 4.4
  Height (cm)                       174 ± 11                                      174 ± 10
  Body weight (kg)                  82 ± 14                                       78 ± 17
  BMI (kg/m^2^)                     26.9 ± 3.4                                    25.1 ± 3.9
  A1C (%)                           7.06 ± 0.98[\*](#t1n1){ref-type="table-fn"}   5.57 ± 0.27
  Waist circumference (cm)          100 ± 10                                      88 ± 19
  Fasting plasma glucose (mmol/L)   8.8 ± 1.9[\*](#t1n1){ref-type="table-fn"}     5.3 ± 0.6
  Fasting plasma insulin (mU/L)     12.1 ± 3.9                                    8.5 ± 2.0
  Serum LDL cholesterol (mg/dL)     119 ± 22                                      146 ± 33
  Serum HDL cholesterol (mg/dL)     62 ± 9                                        59 ± 10
  Plasma triglyceride (mg/dL)       163 ± 80                                      128 ± 79
  GGT (units/L)                     34 ± 17                                       27 ± 9
  AST (units/L)                     22 ± 5                                        24 ± 5

Data are expressed as mean ± SD, unless indicated otherwise.

\**P* \< 0.001, significant differences between groups.

Type 2 diabetic patients showed acceptable glycemic (A1C: 7.06 ± 0.98% vs. 5.53 ± 0.27% in controls; *P* = 0.001) and lipid control on treatment with diet only (*n* = 1), sulfonylurea only (*n* = 3), or combined with metformin (*n* = 5) and statins (*n* = 7). Medications were withdrawn at least 3 days before the measurements. Measurements of fATP and insulin sensitivity were performed on different days under identical conditions of overnight fasting and withdrawal of medications.

Anthropometric measurements {#s7}
---------------------------

Waist circumference was measured with a cloth tape with participants upright. Waist was defined as the midpoint between the highest point of the iliac crest and the lowest part of the costal margin in the midaxillary line ([@B13]).

Analytic procedures {#s8}
-------------------

Plasma glucose was measured by the glucose oxidase method (Glucose Analyzer II, Beckman Instruments Inc., Fullerton, CA) and plasma insulin by double antibody radio immunoassay ([@B11]). All other parameters were measured in the clinical chemistry laboratory with standardized quality-controlled assays.

Peripheral and hepatic insulin sensitivity {#s9}
------------------------------------------

Whole-body glucose disposal (M, or M related to plasma insulin \[M/I\]) and EGP were measured in seven diabetic subjects (three women/four men) and in six controls (four women/two men) as described previously ([@B7]), who exhibited identical demographics as the whole group. Studies started at 6:30 [a.m.]{.smallcaps} with primed-continuous infusion (5 min: 3.6 mg ⋅ kg body wt^−1^ ⋅ fasting glucose \[mg/dL\]/90 \[mg/dL\]; 355 min: 0.036 mg ⋅ min^−1^ ⋅ kg body wt^−1^) of [d]{.smallcaps}-\[6,6-^2^H~2~\]glucose (98% enriched; CIL, Andover, MA). The euglycemic (∼5.5 mmol/L)-hyperinsulinemic (∼70 mU/L) clamp test was started at 10:00 [a.m.,]{.smallcaps} with a primed continuous infusion of human regular insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark; 40 mU ⋅ \[m body surface area\]^−2^ ⋅ min^−1^) for 240 min. A 20% dextrose infusion labeled with [d]{.smallcaps}-\[6,6-^2^H~2~\]glucose (2% enriched) according to the hot-glucose infusion protocol was periodically adjusted to maintain euglycemia ([@B7]).

MRS {#s10}
---

After overnight fasting, volunteers underwent a MRS protocol consisting of two consecutive sessions with a break of ∼30 min in a 3-T MR scanner (Bruker Biospin, Ettlingen, Germany) using a 10-cm linear polarized surface coil tuned to ^1^H and ^31^P frequencies.

In session 1, subjects were supine in the scanner with the coil positioned over the lateral aspect of the liver. Axial and oblique gradient echo images were acquired during one breath-hold each. HCL was measured using localized ^1^H MRS (STEAM, 20 × 20 × 20 mm; 5 scans: echo time, 15, 20, 30, 50, 70 ms; repetition time, 2.5 s) ([Fig. 1*A*](#F1){ref-type="fig"}). Fat and water peaks were integrated after phasing and baseline adjustment using XWIN-NMR software (Bruker Biospin, Ettlingen, Germany). A 30-mm slab within the liver was selected using 1D-ISIS encoding for ^31^P acquisitions ([Fig. 1*A*](#F1){ref-type="fig"}). After a baseline scan, alternated spectra with saturation of the γ-ATP resonance frequency and the frequency mirrored relative to the P~I~ resonance were acquired ([Fig. 1*B*](#F1){ref-type="fig"}). In addition, a combined saturation transfer inversion recovery experiment was performed in each individual to determine the effective longitudinal relaxation time (*T*~1~\*). Spectra were phased and baseline corrected. The peak amplitude was used for quantification because only peak ratios between consecutive scans were used as described ([@B12]).

In session 2, lasting ∼50 min, the subjects were prone in the scanner on top of the surface coil with the lateral aspect of the liver over the coil center. After shimming, gradient echo-based images were acquired during one breath-hold. A 3-dimensional k-space weighted chemical shift imaging sequence (field of view: 20 × 20 × 20 cm, repetition time: 1 s, bandwidth: 5 kHz, 2,048 acquisitions in 34 min) was applied, reconstructed, and quantified offline using custom-made software in combination with jMRUI/AMARES, as described ([@B12],[@B14]).

Calculations and analyses {#s11}
-------------------------

Water and lipid signals were nonlinearly fitted as a single exponential for *T*~2~ correction. HCL were calculated as lipids/(water + lipids) × 100. The chemical exchange constant, *k* of the saturation transfer experiment is assessed from the P~I~ signal before (M~0~) and after saturation of γ-ATP (M~s~). Then, *k* is calculated as *k* = 1/*T*~1~\* × (1 − M~s~/M~0~), and fATP as fATP = *k* × P~I~.

Rates of glucose appearance (Ra) were calculated by dividing the tracer ([d]{.smallcaps}-\[6,6-^2^H~2~\]glucose) infusion rate multiplied by tracer enrichment by the percent of tracer enrichment in plasma and subtracting the tracer infusion rate. During the clamp, Ra was calculated using Steele\'s nonsteady state equations. EGP was calculated from the difference between Ra and mean glucose infusion rates. Insulin-mediated EGP represents EGP during the last 30 min of the clamp. EGP suppression was calculated as 100 × \[(1 − EGP insulin-mediated)/(EGP baseline)\].

Data are presented as means ± SD and compared between the groups using the two-tailed Student *t* test. Relationships between variables were analyzed with Pearson correlations for normally distributed data and with Spearman correlations for the scattered HCL values. Regression analyses for the dependent variables fATP and P~I~ were done using the independent variables of age, BMI, waist circumference, HCL, alanine aminotransferase, A1C, EGP, and FFA suppression, M/I, serum triglycerides, and low-density lipoprotein.

RESULTS {#s12}
=======

Diabetic participants had 67% higher fasting plasma glucose concentrations, 27% higher A1C, and similar body weight, but tended to have greater waist circumference (*P* = 0.167) than controls ([Table 1](#T1){ref-type="table"}). Insulin sensitivity was 29% (M) and 45% (M/I) lower in diabetic volunteers than in controls, confirming peripheral insulin resistance ([Table 2](#T2){ref-type="table"}).

###### 

Liver fat, energy metabolism, and hepatic and peripheral insulin sensitivity

  Variable                                   Type 2 diabetes                             Control
  ------------------------------------------ ------------------------------------------- -------------
  HCL (% signal)                             10.6 ± 9.3                                  8.2 ± 10.9
  Absolute P~I~ (mmol/L)                     0.96 ± 0.19\*                               1.38 ± 0.38
  *k* (s^−1^)                                0.28 ± 0.07                                 0.33 ± 0.12
  fATP (mmol ⋅ L^−1^ ⋅ min^−1^)              16.2 ± 5.2[†](#t2n1){ref-type="table-fn"}   28.0 ± 13.0
  EGP baseline (mg ⋅ kg^−1^ ⋅ min^−1^)       1.6 ± 0.3                                   1.8 ± 0.4
  EGP suppression (%)                        72 ± 15[‡](#t2n2){ref-type="table-fn"}      100 ± 17
  FFA baseline (µmol/L)                      569 ± 122                                   430 ± 260
  FFA suppression (%)                        95 ± 2\*                                    97 ± 2
  M (mg ⋅ kg^−1^ ⋅ min^−1^)                  5.3 ± 1.3[§](#t2n3){ref-type="table-fn"}    7.5 ± 1.9
  M/I (mg ⋅ kg^−1^ ⋅ min^−1^ ⋅ mU^−1^ ⋅ L)   0.06 ± 0.03\|\|                             0.11 ± 0.02

Data are shown as mean ± SD. Significant differences between groups: \**P* = 0.011;

†*P* = 0.025;

‡*P* = 0.009;

§*P* = 0.003;

\|\|*P* = 0.005.

Mean HCL content was not different between groups ([Table 2](#T2){ref-type="table"}). The distribution of the individual HCL values covered a broad range from \<1 to 33% across the groups, with values \>5.5% in six diabetic and five nondiabetic participants. Fasting EGP was similar in both groups, whereas EGP was completely suppressed during insulin stimulation only in controls but not in diabetic participants, indicating hepatic insulin resistance. Fasting plasma FFAs were comparable, but FFA suppression was lower in diabetic patients. Hepatocellular fATP was 42% lower and *k*, the chemical exchange rate constant, tended to be lower in patients compared with controls ([Table 2](#T2){ref-type="table"}). Previous medical treatment with or without metformin did not affect fATP (16.5 ± 6.0 vs. 16.0 ± 5.0 mmol/L/min).

fATP positively correlated with both peripheral (M: *r* = 0.67, *P* = 0.01; M/I: *r* = 0.61, *P* = 0.03) and hepatic insulin resistance (suppression of EGP: *r* = 0.77, *P* = 0.002), even after adjustment for plasma insulin during the clamp (*r* = 0.84, *P* = 0.001) across all participants ([Fig. 2*A*](#F2){ref-type="fig"}). Also, *k* values related to M (*r* = 0.67, *P* = 0.01) but not to M/I (*r* = 0.47, *P* = 0.11). Furthermore, fATP correlated negatively with waist circumference (*r* = −0.78 *P* = 0.001; [Fig. 2*B*](#F2){ref-type="fig"}), fasting plasma glucose (*r* = −0.58, *P* = 0.01), BMI (*r* = −0.55, *P* = 0.02), HCL (*r* = −0.51, *P* = 0.04; [Fig. 2*C*](#F2){ref-type="fig"}), and A1C (*r* = −0.50, *P* = 0.04). Hepatocellular P~I~ (*r* = 0.77, *P* = 0.0003) related positively to fATP ([Fig. 2*D*](#F2){ref-type="fig"}). After adjusting for HCL, the relationships of fATP with waist circumference (*r* = −0.81 *P* = 0.001), M (*r* = 0.66, *P* = 0.02), M/I (*r* = 0.64, *P* = 0.03), EGP suppression (*r* = 0.72, *P* = 0.009), BMI (−0.54, *P* = 0.03), and fasting plasma glucose (*r* = −0.52, *P* = 0.04) remained significant. fATP did not correlate significantly with fasting FFA (*r* = 0.203, *P* = 0.507) or FFA suppression (*r* = 0.51, *P* = 0.07).

![Correlations with hepatocellular ATP production (fATP) with (A) hepatic insulin resistance (EGP suppression; all: r = 0.77, P = 0.002; type 2 diabetic subjects: r = 0.79, P = 0.01; controls: r = 0.54, P = 0.17), (B) waist circumference (all: r = −0.78, P = 0.001; type 2 diabetic subjects: r = 0.57, P = 0.11; controls: r = 0.68, P = 0.064), (C) HCL contents (all: r = −0.51, P = 0.038; type 2 diabetic subjects r = −0.20, P = 0.61; controls: r = 0.62, P = 0.10), (D) hepatic concentrations of P~I~ (all: r = 0.77, P = 0.0003; type 2 diabetic subjects: r = 0.57, P = 0.11; controls: r = 0.68, P = 0.064) across all participants (type 2 diabetic subjects: ●, controls: △).](448fig2){#F2}

Multiple regression analysis for the dependent variable fATP identified waist circumference as the independent predictor of fATP (*r*^2^ = 0.65, adjusted *r*^2^ = 0.62, *P* = 0.001). Likewise, multiple regression analysis for the dependent variable P~I~ identified waist circumference as the independent predictor of P~I~ (*r*^2^ = 0.56, adjusted *r*^2^ = 0.52, *P* = 0.003).

CONCLUSIONS {#s13}
===========

This study found that patients with type 2 diabetes have markedly lower hepatic ATP production than nondiabetic individuals of comparable age and body mass. Of note, this alteration of fATP occurred without evidence for clinical liver disease, as indicated by the lack of a history of hepatitis, alcohol consumption, or significant elevation of liver enzymes ([@B11]).

Across all subjects, hepatocellular fATP correlated negatively with HCL, as recently reported for the relationships between hepatic absolute P~I~ and ATP concentrations and HCL ([@B11]). However, we detected a clear difference in fATP between diabetic and nondiabetic participants, despite comparable HCL values and equal distribution of steatosis (HCL \>5.5%) in both groups (67% of diabetic and 63% of nondiabetic participants). Thus, other factors than HCL more likely explain the lower fATP in patients. After adjustment for HCL, hepatic and whole-body insulin sensitivity remained tightly and negatively related to fATP.

Absolute hepatic concentrations of P~I~ and ATP are also associated with hepatic but not with peripheral insulin sensitivity ([@B11]). Under similar conditions of overnight fasting, myocellular fATP correlates negatively to peripheral insulin sensitivity, which is mostly accounted for by skeletal muscle, but not to hepatic insulin sensitivity ([@B7]). This suggests that hepatocellular fATP could serve as a better indicator of overall insulin resistance than myocellular fATP.

In type 2 diabetes, insulin resistance develops as a result of inherited factors as well as from acquired factors that result in glucolipotoxicity due to chronic elevation of FFAs, triglycerides, or glucose ([@B2],[@B3]). In rats, a high-fat diet for 7 weeks induced obesity, insulin resistance, and hepatic steatosis and also reduced respiratory capacity and increased oxidative stress in liver mitochondria ([@B15]). Further, mitochondria from fatty rat liver have lower amounts of ATP synthase protein ([@B16]). A short-term high-fat diet also leads to insulin resistance in liver, but not in skeletal muscle ([@B17]), whereas a hypocaloric diet decreases both hepatic fat content and insulin resistance within 48 h ([@B18]). In conclusion, impaired energy metabolism in the liver could be an early defect in the pathogenesis of type 2 diabetes.

The lack of a correlation of fATP with circulating plasma triglycerides or FFAs suggests that increased lipid availability cannot explain the abnormality of hepatic fATP. However, hepatocellular fATP related negatively to BMI and even more tightly to waist circumference, which explained most of the variation of fATP. Of note, waist circumference is the best anthropometric marker of abdominal visceral fat ([@B19]), which suggests, but does not prove, a role of visceral fat for hepatic energy metabolism.

Hepatocellular fATP further related to short- and long-term glycemia, as measured by fasting plasma glucose and A1C, so that defective hepatic energy metabolism could also reflect deterioration of glucose metabolism in the progression of type 2 diabetes. Abnormalities in fATP have been found in skeletal muscle not only of patients with overt type 2 diabetes ([@B7],[@B20]) but also of their nondiabetic first-degree relatives, who are at increased risk for type 2 diabetes ([@B8]). Impairment of ATP synthesis in skeletal muscle has been further related to insulin resistance, myocellular lipid deposition, and genetic susceptibility to the onset of type 2 diabetes ([@B21]). To our knowledge, however, no data on a similar association between lipid contents, insulin sensitivity, and ATP production, which also includes ATP generation from glycolytic flux, have been reported in the livers of patients with type 2 diabetes. Although our results suggest that abnormal phosphorus metabolism relates to hepatic insulin resistance and HCL, we cannot rule out that reduced ATP turnover is rather a consequence of reduced energy demand or altered energy homeostasis that may relate to increased lipid availability and hyperglycemia. In this case, impaired fATP would result from chronic hyperglycemia and/or insulin resistance due to glucose toxicity. Of note, there is evidence that insulin stimulates uptake of P~I~ by way of a sodium-dependent transporter, at least in cultured rat hepatocytes, so that desensitization of this system could lead to lower hepatocellular P~I~ levels ([@B22]).

Our MRS protocol is time-consuming, which also explains the dropout rate in this study. Alternatively, the tight relationship between hepatocellular fATP and P~I~, which is a direct consequence of a comparable rate constant, *k*, suggests that quantification of the absolute P~I~ concentration could be sufficient for assessing hepatic energy metabolism. Altered tissue morphology could affect the MR relaxation rates, which in turn could affect the absolute quantification of metabolites and fATP. This simplification should, therefore, only be considered when there is strong evidence against alterations in MR relaxation times. The tight correlation between ATP and P~I~ ([@B11]) renders errors due to altered MR relaxation times highly unlikely. Participants in the current study did not show clinical signs of cholestasis or impaired liver function, as expressed by normal results on liver enzyme tests and function parameters, although we cannot be completely certain because we had no histologic confirmation. Thus, absolute quantification of hepatic ^31^P metabolites ([@B11],[@B12]), together with *k* from this study, appears to be a clinically applicable measure of hepatic energy metabolism. Even more, it appears that waist circumference could also serve as a viable predictor of hepatic ATP production.

Nevertheless, some limitations of the current study need to be considered. We studied elderly volunteers who had a mean age of \~60 years, which might result in lower fATP analogous to data on myocellular fATP ([@B8]). The ages of diabetic and nondiabetic participants in this study were similar, however, and fATP in these elderly controls was almost identical to that previously reported for young, lean, healthy volunteers ([@B12]).

Finally, the saturation transfer experiment provides a measure of total ATP turnover, which includes cycling at the levels of glyceraldehyde-3-phosphate dehydrogenase and 3-phosphoglycerate kinase of the glycolytic and gluconeogenic pathways ([@B23]). Because fasting EGP was comparable between both groups, despite different degrees of glycemia, a variable contribution of cycling is rather unlikely. Finally, some spectra of the saturation transfer experiment contained residual phosphocreatine resulting from a minor compromise between optimizing localization and signal-to-noise ratio. Of note, the phosphocreatine is dominating skeletal muscle spectra, implying the contamination in P~I~, which determines fATP, is lower by an order of magnitude. Moreover, chemical shift displacement shifts the P~I~ signal further inward into the liver. The phosphodiester signals appear affected by the saturation pulse ([Fig. 1*A*](#F1){ref-type="fig"}); this could, besides off-resonance effects, indicate chemical exchange such as ATP used in phosphodiesterase formation ([@B24]).

In conclusion, patients with type 2 diabetes without clinical liver disease exhibit lower ATP production than nondiabetic otherwise comparable individuals. The reduction in flux through ATP synthesis depends primarily on the lower hepatic P~I~ and ATP concentrations. Insulin resistance relates to the perturbed hepatic energy metabolism, which can be at least be partly explained by fat mass as assessed from waist circumference.
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